Intersect Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $3.68M | Sell |
23,998
-1,755
| -7% | -$268K | 1.11% | 13 |
|
|
2022
Q1 | $4.17M | Buy |
25,753
+1,803
| +8% | +$262K | 0.8% | 17 |
|
|
2021
Q4 | $3.24M | Sell |
23,950
-3,181
| -12% | -$376K | 0.6% | 31 |
|
|
2021
Q3 | $2.93M | Sell |
27,131
-32
| -0.1% | -$3.66K | 0.5% | 41 |
|
|
2021
Q2 | $3.06M | Buy |
27,163
+1,975
| +8% | +$222K | 0.54% | 38 |
|
|
2021
Q1 | $2.73M | Sell |
25,188
-381
| -1% | -$40.8K | 0.55% | 38 |
|
|
2020
Q4 | $2.74M | Buy |
25,569
+635
| +3% | +$61K | 0.6% | 36 |
|
|
2020
Q3 | $2.18M | Buy |
24,934
+1,010
| +4% | +$95.1K | 0.59% | 36 |
|
|
2020
Q2 | $2.35M | Buy |
23,924
+1,147
| +5% | +$101K | 0.76% | 30 |
|
|
2020
Q1 | $1.74M | Buy |
22,777
+3,685
| +19% | +$314K | 0.69% | 35 |
|
|
2019
Q4 | $1.69M | Sell |
19,092
-122
| -0.6% | -$10.1K | 0.57% | 38 |
|
|
2019
Q3 | $1.46M | Sell |
19,214
-6,627
| -26% | -$454K | 0.54% | 41 |
|
|
2019
Q2 | $1.88M | Buy |
25,841
+346
| +1% | +$27.2K | 0.73% | 31 |
|
|
2019
Q1 | $2.06M | Sell |
25,495
-2,445
| -9% | -$200K | 0.87% | 30 |
|
|
2018
Q4 | $2.58M | Buy |
27,940
+1,838
| +7% | +$162K | 1.23% | 22 |
|
|
2018
Q3 | $2.47M | Buy |
26,102
+1,169
| +5% | +$111K | 1.08% | 25 |
|
|
2018
Q2 | $2.31M | Buy |
24,933
+1,735
| +7% | +$169K | 1.11% | 25 |
|
|
2018
Q1 | $2.2M | Buy |
23,198
+1,940
| +9% | +$213K | 1.16% | 26 |
|
|
2017
Q4 | $2.06M | Buy |
21,258
+941
| +5% | +$88.7K | 1.11% | 26 |
|
|
2017
Q3 | $1.8M | Buy |
20,317
+776
| +4% | +$59.1K | 1.02% | 28 |
|
|
2017
Q2 | $1.42M | Buy |
19,541
+7,799
| +66% | +$524K | 0.85% | 34 |
|
|
2017
Q1 | $765K | Buy |
11,742
+642
| +6% | +$40.4K | 0.67% | 38 |
|
|
2016
Q4 | $695K | Buy |
11,100
+391
| +4% | +$23.9K | 0.52% | 44 |
|
|
2016
Q3 | $675K | Buy |
10,709
+1,070
| +11% | +$69.3K | 0.53% | 44 |
|
|
2016
Q2 | $597K | Buy |
9,639
+2,857
| +42% | +$174K | 0.36% | 53 |
|
|
2016
Q1 | $387K | Buy |
6,782
+1,235
| +22% | +$68.8K | 0.24% | 78 |
|
|
2015
Q4 | $329K | Buy |
5,547
+237
| +4% | +$13.7K | 0.28% | 70 |
|
|
2015
Q3 | $289K | Buy |
5,310
+1,002
| +23% | +$65.2K | 0.27% | 74 |
|
|
2015
Q2 | $290K | Buy |
4,308
+176
| +4% | +$11.5K | 0.25% | 74 |
|
|
2015
Q1 | $267K | Buy |
4,132
+2,052
| +99% | +$124K | 0.21% | 73 |
|
|
2014
Q4 | $136K | Buy |
+2,080
| New | +$131K | 0.11% | 105 |
|
Other funds holding ABBV
Intersect Capital's ABBV Position: Q2 2022 in Review
Intersect Capital reduced its AbbVie (ABBV) stake by 6.8% in Q2 2022, selling an estimated $268K and leaving 23,998 shares worth $3.68M. The position accounts for 1.11% of the portfolio, ranked #13.
Intersect Capital first reported a position in ABBV in Q4 2014 and has held it in 31 quarters since. The position peaked at $4.17M in Q1 2022. 3,005 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.
- Intersect Capital held 23,998 shares of AbbVie worth $3.68M as of Q2 2022.
- Intersect Capital sold 1,755 AbbVie shares in Q2 2022, an estimated $268K.
- AbbVie made up 1.11% of Intersect Capital's portfolio in Q2 2022, its #13 holding.
- Intersect Capital first reported a position in AbbVie in Q4 2014 and has held it in 31 quarters since.
- Intersect Capital's AbbVie position peaked at $4.17M in Q1 2022.
- 3,005 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.
Based on Intersect Capital's 13F filing for Q2 2022, filed 2 Sep 2022.